Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.19), FiscalAI reports.
Dermata Therapeutics Price Performance
Shares of NASDAQ:DRMA traded down $0.04 during trading on Tuesday, hitting $1.08. 18,229,723 shares of the company were exchanged, compared to its average volume of 986,420. The stock has a 50 day moving average of $1.25 and a 200 day moving average of $1.37. Dermata Therapeutics has a 52-week low of $0.95 and a 52-week high of $6.58. The company has a market cap of $4.34 million, a PE ratio of -0.20 and a beta of 0.66.
Institutional Investors Weigh In On Dermata Therapeutics
A hedge fund recently bought a new position in Dermata Therapeutics stock. Clear Street Group Inc. bought a new position in Dermata Therapeutics, Inc. (NASDAQ:DRMA – Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 17,000 shares of the company’s stock, valued at approximately $39,000. Clear Street Group Inc. owned about 0.60% of Dermata Therapeutics as of its most recent SEC filing. Institutional investors own 8.67% of the company’s stock.
Analyst Ratings Changes
View Our Latest Research Report on Dermata Therapeutics
Dermata Therapeutics Company Profile
Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.
At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques.
Read More
- Five stocks we like better than Dermata Therapeutics
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
